

Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Mesalazine (Octasa®)
Indication under review	Treatment of mild to moderate inflammatory bowel disease and maintenance of remission
Policy No:	APC 004
Date of Issue/Date of re-issue:	May 2013, May 2015
Review Date:	May 2018
Policy Statement: Octasa® is recommended as the first line oral 5-aminosalicylate. This is applicable to new patients or patients requiring a switch from Mesren® MR.	
Traffic Light Status	Green
Key Points considered:	
<ul style="list-style-type: none"> • Since December 2012, Octasa MR has replaced Mesren MR, a pharmaceutically identical equivalent which is no longer manufactured. • Octasa® MR represents the least expensive, pH-dependent, modified-release mesosalazine product in the UK. • Octasa® MR is first line within Berkshire East. 	
References:	
<ol style="list-style-type: none"> 1. Mowat C et al on behalf of the IBD section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60:571-607 . 2. Travis SPL et al for the European Crohn's and Colitis Organisation. European evidence-based consensus on the management of ulcerative colitis: what are the implications of the new formulations? J Clin Gastroenterology 2008; 42:338-44. 3. Fadda HM, Basit AW. Dissolution of pH responsive formulations in media resembling intestinal fluids: bicarbonate vs phosphate buffers. J Drug Del sci Tech 2005; 15:273-9. 	
Date taken to APC:	1 st May 2013
Date Ratified by MMC on Behalf of the Board:	10 th July 2013
Expired policy reviewed by APC	6 th May 2015
Date ratified by GP MOC	17 th June 2015